Editorial

Duloxetine-Induced Tako-Tsubo Cardiomyopathy: Implications for Preventing a Broken Heart

Authors: Richard G. Trohman, MD, Christopher Madias, MD

Abstract

Agatha Christie captured her readers with mystery. Robert Ripley fascinated us with a vast assortment of the bizarre and unusual. It is, therefore, not surprising that we are intrigued by the unsolved puzzle of tako-tsubo cardiomyopathy. In this issue of the Southern Medical Journal, Rotondi et al. help extend the spectrum of pharmacologic agents with potential to precipitate this syndrome.1

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Rotondi F, Manganelli F, Carbone G, et al. "Tako-tsubo" cardiomyopathy and duloxetine use. South Med J 2011;104:345-347.
 
2. Dote K, Sato H, Tateishi H, et al. Myocardial stunning due to simultaneous multivessel coronary spasms: a review of 5 cases [in Japanese]. J Cardiol 1991;21:203-214.
 
3. Virani S, Khan AN, Mendoza CE, et al. Takotsubo cardiomyopathy, or broken-heart syndrome. Tex Heart Inst J 2007;34:76-79.
 
4. Sharkey SW, Windenburg DC, Lesser JR, et al. Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J Am Coll Cardiol 2010;55:333-341.
 
5. Wittstein IS, Thiemann DR, Lima JA, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 2005;352:539-548.
 
6. Colucci VJ, Berry BD. Heart failure worsening and exacerbation after venlafaxine and duloxetine therapy. Ann Pharmacother 2008;42:882-886.
 
7. Lantz RJ, Gillespie TA, Rash TJ, et al. Metabolism, excretion and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 2003;31:1142-1150.
   
9. Bergman BR, Reynolds HR, Skolnick AH, et al. A case of apical ballooning cardiomyopathy associated with duloxetine. Ann Intern Med 2008;149:218-219.
 
10. Depression statistics. Available at: http://www.depressionstatistics.org/. Accessed January 26, 2011.